

REFERENCES

1. Ashfaq Ul Hassan, Ghulam Hassan, Zahida Rasool. Role of Stem Cells in Treatment of Neurological Disorder. *International Journal of Health Sciences* 2009;3(2):227–33.
2. Lin Q, Wesson RN, Maeda H, Wang Y, Cui Z, Liu JO, Cameron AM, Gao B, Montgomery RA, Williams GM, Sun Z. Pharmacological Mobilization of Endogenous Stem Cells Significantly Promotes Skin Regeneration after Full Thickness Excision: The Synergistic Activity of AMD3100 and Tacrolimus. *J Invest Dermatol* 2014;134(9):2458–68.
3. Nandoe Tewarie RS, Hurtado A, Bartels RH, Grotenhuis A, Oudega M. Stem Cell–Based Therapies for Spinal Cord Injury. *The Journal of Spinal Cord Medicine*. 2009;32(2):105–14.
4. Frederich BJ, Timofeyev V, Thai PN, Haddad MJ, Poe A, Lau VC, et al. Electrotaxis of Cardiac Progenitor Cells, Cardiac Fibroblasts, and Induced Pluripotent Stem cell-derived Cardiac Progenitor Cells requires serum and is directed via PI3K pathways. *Heart_Rhythm* 2017;S1547-5271(17)30840-8.
5. Tao ZY, Gao P, Yan YH, Li HY, Song J, Yang JX. Osthole Enhances the Therapeutic Efficiency of Stem Cell Transplantation in Neuroendoscopy Caused Traumatic Brain Injury. *Biol Pharm Bull* 2017;40(7):1043-54.
6. Vidarsson H, Hyllner J, Sartipy P. Differentiation of human embryonic stem cells to cardiomyocytes for in vitro and in vivo applications. *Stem Cell Rev* 2010;6(1):108-20.
7. Aaron Nauth and Emil H Schemitsch. Stem cells for the repair and regeneration of bone. *Indian J Orthop* 2012;46(1):19–21.
8. Anderson DJ. Stem Cells and Pattern Formation in the Nervous System: The Possible versus the Actual. *Neuron* 2001;30(1):19-35.
9. Ballard VL, Edelberg JM. Stem cells and the regeneration of the aging cardiovascular system. *Circ Res* 2007;100(8):1116-27.

10. Xu S, Höglund M, Håkansson L, Venge P. Granulocyte colony-stimulating factor (G-CSF) induces the production of cytokines in vivo. *Br J Haematol* 2000;108(4):848-53.
11. Gargiulo C, Pham VH, Nguyen KCD, Trieu VLH, Duy TH. Autologous Peripheral Blood Stem Cells Increase the Telomere Length in Patient: A Case Report of 13 Patients. *J Stem Cell Res Ther* 2016;6(8):1-6.
12. Steven W Lane, David A Williams, Fiona M Watt. Modulating the stem cell niche for tissue regeneration. *Nat Biotechnol* 2014;32(8):795–803.
13. Aurora AB, Olson EN. Immune Modulation of Stem Cells and Regeneration. *Cell Stem Cell* 2014;15(1):14-25.
14. Karp JM, Leng Teo GS. Mesenchymal Stem Cell Homing: The Devil Is in the Details. *Cell Stem Cell* 2009;4(3):206-16.
15. Wagner W, Horn P, Bork S, Ho AD. Aging of hematopoietic stem cells is regulated by the stem cell niche. *Exp Gerontol* 2008 43(11):974-80.
16. Zhang C, Chen X, Zhang X, Gao L, Kong P et al, “Mobilization of peripheral blood stem cells for autologous transplantation patients with hematological malignancies: Influence of disease, mobilization method, age and sex. *Transfus Apher Sci* 2008;39(1):21-8
17. Metallo CM. Engineering the stem cell microenvironment. *Biotechnol Prog* 2007;23(1):18-23.
18. Asahara T. Isolation of putative progenitor endothelial cells for angiogenesis. *Science* 1997;275(5302):964-7.
19. Min Zhang. The multi-differentiation potential of peripheral blood mononuclear cells. *Stem Cell Res Ther* 2012;3(6): 48.
20. Badorff C. Transdifferentiation of blood-derived human adult endothelial progenitor cells into functionally active cardiomyocytes. *Circulation* 2003;107(7):1024-32
21. Simper D. Smooth muscle progenitor cells in human blood. *Circulation* 2002;106(10):1199-204.
22. Hu G, Xu JJ, Deng ZH, Feng J, Jin Y. Supernatant of bone marrow mesenchymal stromal cells induces peripheral blood mononuclear cells possessing mesenchymal features. *Int J Biol Sci* 2011;7(3):364-75.

23. Wan C, He Q, Li G. Allogenic peripheral blood derived mesenchymal stem cells (MSCs) enhance bone regeneration in rabbit ulna critical-sized bone defect model,” *Journal of Orthopaedic Research. J Orthop Res* 2006;24(4):610-8.
24. Dellambra E. Downregulation of 14-3-3sigma prevents clonal evolution and leads to immortalization of primary human keratinocytes. *J Cell Biol* 2000;149(5):1117-30.
25. Horschitz S, “Generation of neuronal cells from human peripheral blood mononuclear cells. *Neuroreport* 2010;21(3):185-90
26. Fahey TR. Cytokine production in a model of wound healing: the appearance of MIP-1, MIP-2, cachectin/TNF and IL-1. *Cytokine* 1990;2(2):92-9.
27. Dayalu P, Albin RL. Huntington disease: pathogenesis and treatment. *Neurologic Clinics* 2015;33(1):101–14.
28. Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. *Autoimmun Rev* 2010;9(5):387–94.
29. Sveinbjornsdottir S. The clinical symptoms of Parkinson's disease. *Journal of Neurochemistry* 2016;139:318–24.
30. Mendez MF. Early-onset Alzheimer's disease: nonamnestic subtypes and type 2 AD. *Archives of Medical Research* 2012; 43(8):677–85.
31. Richard A C Hughes. Clinical review: Peripheral neuropathy. *British Medical Journal* 2002;324(7335):466–69.
32. Kurt A, Jellinger. Basic mechanisms of neurodegeneration: a critical update. *J. Cell. Mol. Med* 2010;14(3):457-87.
33. Goetz CG. The history of Parkinson’s disease: early clinical descriptions and neurological therapies. *Cold Spring Harb Perspect Med* 2011;1:a008862.
34. Anne G. Osborn, Karen L. Salzman, A. James Barkovich. *Diagnostic Imaging: Brain*: Published by Amirsys Second Edition. *Br J Radiol* 2010;83(989):450–51.
35. Lorraine V Kalia, Anthony E Lang. Parkinson’s disease. *The lancet* 2015;386(9996):896-912.
36. Jankovic J, McDermott M, Carter J. Variable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. *Neurology* 1990;40:1529–34.

37. Marras C, Lang A. Parkinson's disease subtypes: lost in translation? *J Neurol Neurosurg Psychiatry* 2013;84:409–15.
38. Khoo TK, Yarnall AJ, Duncan GW. The spectrum of nonmotor symptoms in early Parkinson disease. *Neurology* 2013;80:276–81.
39. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR, NMSS Validation Group. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. *Mov Disord* 2011;26:399–406.
40. Duncan GW, Khoo TK, Yarnall AJ. Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms. *Mov Disord* 2014;29:195–202.
41. Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. *Autoimmun Rev* 2010;9(5):387–94.
42. Coles A. Multiple sclerosis. *Lancet* 2008;372(9648):1502–17.
43. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis results of an international survey. *Neurology* 1996;46(4):907–11.
44. Fred D. Defining the clinical course of multiple sclerosis. *Neurology* 2014;83(3):278–86.
45. Johansson BB. Regeneration and plasticity in the brain and spinal cord. *J Cereb Blood Flow Metab* 2007;27:1417–30.
46. Auld DS, Mennicken F, Quirion R. Nerve growth factor rapidly induces prolonged acetylcholine release from cultured basal forebrain neurons: differentiation between neuromodulatory and neurotrophic influences. *J Neurosci* 2001;21:3375–82.
47. Baquet ZC, Bickford PC, Jones KR. Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. *J Neurosci* 2005;25:6251–59.
48. Thickbroom GW, Mastaglia FL. Plasticity in neurological disorders and challenges for noninvasive brain stimulation (NBS). *J Neuroeng Rehabil* 2009;6:4.
49. Smith DE, Roberts J, Gage FH, Tuszynski MH. Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy. *Proc Natl Acad Sci USA* 1999;96:10893–898.

50. Tuszynski MH, Thal L, Pay M, Salmon DP, U HS, Bakay R, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. *Nat Med* 2005;11:551-55.
51. Joseph, T.B. Disposition of flavonoids via enteric recycling: enzyme stability affects characterization of prunetin glucuronidation across species, organs, and UGT isoforms. *Mol. Pharm* 2007;4:883-94.
52. Ramos, S. Effects of dietary flavonoids on apoptotic pathways related to cancer chemoprevention. *J. Nutr. Biochem* 2007;18:427-42.
53. Halliwell B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. *Drugs Aging* 2001;18:685-716.
54. Kay CD. The future of flavonoid research. *Br. J. Nutr* 2010;104:S91-S5.
55. Koh SH, Lee SM, Kim HY, Lee KY, Lee YJ, Kim HT. The effect of epigallocatechin gallate on suppressing disease progression of ALS model mice. *Neurosci. Lett* 2006;395:103-7.
56. Ortega-Arellano HF, Jimenez-Del-Rio M, Velez-Pardo C. Life span and locomotor activity modification by glucose and polyphenols in *Drosophila melanogaster* chronically exposed to oxidative stress-stimuli: implications in Parkinson's disease. *Neurochem. Res* 2010;36:1073-86.
57. Ebrahimi A, Schluesener H. Natural polyphenols against neurodegenerative disorders: Potentials and pitfalls. *Ageing Research Reviews* 2010;11:329-45.
58. Mandel SA, Amit T, Weinreb O, Reznichenko L, Youdim MB. Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases. *CNS Neurosci Ther* 2008;14:352-65.
59. Dechsupa S, Kothan S, Vergote J, Leger G, Martineau A, Berangeo S, et al. Quercetin, Siamois 1 and Siamois 2 induce apoptosis in human breast cancer MDA-mB-435 cells xenograft in vivo. *Cancer Biology & Therapy* 2007;6(1):56-61.
60. Suttana W, Mankhetkorn S, Poompimon W, Palagani A, Zhokhov S, Gerlo S, et al. Differential chemosensitization of P-glycoprotein overexpressing K562/Adr cells by with aferin A and Siamois polyphenols. *Molecular Cancer* 2010;9(9):1-22.

61. Khonkarn R, Mankhetkorn S, Hennink WE, Okonogi S. PEG-OCL micelles for quercetin solubilization and inhibition of cancer cell growth. *European journal of pharmaceutics and biopharmaceutics* 2011;79(2):268-75.
62. Okonogi S, Khonkarn R, Mankhetkorn S, Unger FM, Viernstein H. Antioxidant activity and cytotoxicity of *Cyrtosperma johnstonii* extracts on drug sensitive and resistant leukemia and small cell lung carcinoma cells. *Pharmaceutical biology* 2013;51(3):329-38.
63. Kothan S, Loetchutinat C, Dechsupa S, Moretti J-L, Mankhetkorn S. Quercetin induce ROSi depletion, impairment the mitochondrial function and apoptosis in K562 and K562/adr cells. *Bulletin Chiang Mai Associated Medical Sciences* 2006; 39(2):113-117.
64. Khonkarn R, Mankhetkorn S, Talelli M, Hennink WE, Okonogi S. Cytostatic effect of xanthone-loaded mPEG-b-p(HPMAM-Lac2) micelles towards doxorubicin sensitive and resistant cancer cells. *Colloids Surf B Biointerfaces* 2012;94:266-73.
65. Dechsupa S, Kothan S, Vergote J, Leger G, Martineau A, Beranger S, et al. Quercetin, extracts of mamoa wood and Siamois? red wine induce apoptosis in human breast cancer MDA-MB-435 cells xenografts in vivo. *Journal of Cancer Biology and Therapy* 2007; 6(1):56-61.
66. Yin T, Li L. The stem cell niches in bone. *Journal of Clinical Investigation* 2006;116:1195–1201.
67. Louis M. Peripheral blood stem cell mobilization: new regimens, new cells, where do we stand. *Curr Opin Hematol* 2008;15(4):285–92.
68. Tzannou I, Leen AM. Preventing stem cell transplantation-associated viral infections using T-cell therapy. *Immunotherapy* 2015;7(7):793–810.
69. Damon LE, Damon LE. Mobilization of hematopoietic stem cells into the peripheral blood. *Expert Rev Hematol* 2009;2:717-33.
70. Jun Seita, Irving L. Weissman. Hematopoietic Stem Cell: Self-renewal versus Differentiation. *Wiley Interdiscip Rev Syst Biol Med* 2010;2(6):640–53.
71. Dimarino AM, Caplan AI, Bonfield TL. Mesenchymal stem cells in tissue repair. *Front. Immunol* 2013;4(201).

72. Seita J, Irving L. Hematopoietic Stem Cell: Self-renewal versus Differentiation. Wiley Interdiscip Rev Syst Biol Med 2010;2(6):640–53.
73. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964-67.
74. Zvaifl er NJ, Marinova-Mutafchieva L, Adams G, Edwards CJ, Moss J, Burger JA, et al. Mesenchymal precursor cells in the blood of normal individuals. Arthritis Res 2000;2:477-88.
75. Costa-Rodrigues J, Teixeira CA, Sampaio P, Fernandes MH. Characterization of the osteoclastogenic potential of human osteoblastic and fibroblastic conditioned media. J Cell Biochem 2010;109:205-16.
76. Hu G, Xu JJ, Deng ZH, Feng J, Jin Y. Supernatant of bone marrow mesenchymal stromal cells induces peripheral blood mononuclear cells possessing mesenchymal features. Int J Biol Sci 2011;7:364-75.
77. Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1994;1:71-81.
78. Reitz C, Rogaeva E, Foroud T, Farrer LA. Genetics and genomics of late-onset Alzheimer's disease and its endophenotypes. Int J Alzheimers Dis 2011;1:284728.
79. Zhang J, Keene CD, Pan C, Montine KS, Montine TJ. Proteomics of Human Neurodegenerative Diseases. J Neuropathol Exp Neurol 2008;67(10):923–32.
80. Jacobs JM, Adkins JN, Qian WJ, Liu T, Shen Y, Camp DG, et al. Utilizing human blood plasma for proteomic biomarker discovery. J. Proteome Res 2005;4(4):1073-85.
81. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 2002;1(11): 845-67.
82. Pieper R, Gatlin CL, Makusky AJ, Russo PS, Schatz CR, Miller SS. The human serum proteome: display of nearly 3700 chromatographically separated protein spots on two-dimensional electrophoresis gels and identification of 325 distinct proteins. Proteomics 2003;3(7):1345-64.
83. Radulovic D, Jelveh S, Ryu S, Hamilton TG, Foss E, Mao Y, et al. Informatics platform for global proteomic profiling and biomarker discovery using liquid

- chromatography-tandem mass spectrometry. *Mol. Cell. Proteomics* 2004;3(10):984-97.
84. Li J. Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. *Clin. Chem* 2005;51(12):2229-35.
85. Allard L. PARK7 and nucleoside diphosphate kinase A as plasma markers for the early diagnosis of stroke. *Clin. Chem* 2005;51(11):2043-51.
86. Zimmermann-Ivol CG, Burkhard PR, Le Floch-Rohr J, Allard L, Hochstrasser DF, Sanchez JC. Fatty acid binding protein as a serum marker for the early diagnosis of stroke: a pilot study. *Mol. Cell. Proteomics* 2004;3(1):66-72.
87. Thongboonkerd V. Proteomics and diabetic nephropathy. *Contrib Nephrol* 2004;141:142-54.
88. Noh KS, Lee DY, Cha JH. Toxicoproteomics in the study of aromatic hydrocarbon toxicity. *Proteomics* 2004;4:3505.
89. O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. *J. Biol. Chem* 1975;250:4007-21.
90. Godovac-Zimmermann, L.R. Brown. Perspectives for mass spectrometry and functional proteomics. *Mass Spectrum Rev* 2001;10:1-57.
91. Cristea IM, Gaskell SJ, Whetton AD. Human blood plasma preparation for two-dimensional gel electrophoresis. *Blood* 2004;103:3824-30.
92. Hoehn M, Yahr ML. Parkinsonism: onset, progression and mortality. *Neurology* 1967;17(5):427-42.
93. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). *Neurology* 1983;33(11):1444-52.
94. Jennifer L, Shadrach, Amy J Wagers. Stem cells for skeletal muscle repair. *Phil. Trans. R. Soc. B.* 2001;366:2297-2306.
95. Barile L, Messina E, Giacomello A, Marbán E. Endogenous Cardiac Stem Cells. *Prog Cardiovasc Dis.* 2007;50(1):31-48.
96. Jin K, Galvan V. Endogenous neural stem cells in the adult brain. *J Neuroimmune Pharmacol.* 2007;2(3):236-42.